Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Author
González-Martín, AntonioPothuri, Bhavana
Vergote, Ignace
DePont Christensen, René
Graybill, Whitney
Mirza, Mansoor R
McCormick, Colleen
Lorusso, Domenica
Hoskins, Paul
Freyer, Gilles
Baumann, Klaus
Jardon, Kris
Redondo, Andrés
Moore, Richard G
Vulsteke, Christof
O'Cearbhaill, Roisin E
Lund, Bente
Backes, Floor
Barretina-Ginesta, Pilar
Haggerty, Ashley F
Rubio-Pérez, Maria J
Shahin, Mark S
Mangili, Giorgia
Bradley, William H
Bruchim, Ilan
Sun, Kaiming
Malinowska, Izabela A
Li, Yong
Gupta, Divya
Monk, Bradley J
Affiliation
Univ Arizona, Coll Med, Arizona Oncol US Oncol NetworkIssue Date
2019-09-28
Metadata
Show full item recordPublisher
MASSACHUSETTS MEDICAL SOCCitation
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., … Monk, B. J. (2019). Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 381(25), 2391–2402. https://doi.org/10.1056/nejmoa1910962 Journal
NEW ENGLAND JOURNAL OF MEDICINERights
Copyright © 2019 Massachusetts Medical Society.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence of BRCA mutations. The efficacy of niraparib in patients with newly diagnosed advanced ovarian cancer after a response to first-line platinum-based chemotherapy is unknown.Note
6 month embargo; published online: 28 September 2019ISSN
0028-4793PubMed ID
31562799Version
Final published versionSponsors
GlaxoSmithKlineae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1910962
Scopus Count
Collections
Related articles
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
- Authors: Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA, ENGOT-OV16/NOVA Investigators
- Issue date: 2016 Dec 1
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
- Authors: Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU, AVANOVA investigators
- Issue date: 2019 Oct
- Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
- Authors: Valabrega G, Pothuri B, Oaknin A, Graybill WS, Sánchez AB, McCormick C, Baurain JF, Tinker AV, Denys H, O'Cearbhaill RE, Hietanen S, Moore RG, Knudsen AØ, de La Motte Rouge T, Heitz F, Levy T, York W, Gupta D, Monk BJ, González-Martín A
- Issue date: 2024 Aug
- Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
- Authors: Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A
- Issue date: 2024 May
- Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
- Authors: Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR
- Issue date: 2018 Aug
